Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Posted: October 7, 2024 at 2:37 am

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its previously announced proposed acquisition of Clairvoyant Therapeutics, Inc. Following the completion of necessary due diligence and other pre-closing activities specified in the conditional binding term sheet that was announced on September 9, 2024, Psyence Biomed has decided not to proceed with the acquisition at this time.

See the rest here:
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Related Posts